756 related articles for article (PubMed ID: 17664471)
1. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.
Khambata-Ford S; Garrett CR; Meropol NJ; Basik M; Harbison CT; Wu S; Wong TW; Huang X; Takimoto CH; Godwin AK; Tan BR; Krishnamurthi SS; Burris HA; Poplin EA; Hidalgo M; Baselga J; Clark EA; Mauro DJ
J Clin Oncol; 2007 Aug; 25(22):3230-7. PubMed ID: 17664471
[TBL] [Abstract][Full Text] [Related]
2. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab.
Jacobs B; De Roock W; Piessevaux H; Van Oirbeek R; Biesmans B; De Schutter J; Fieuws S; Vandesompele J; Peeters M; Van Laethem JL; Humblet Y; Pénault-Llorca F; De Hertogh G; Laurent-Puig P; Van Cutsem E; Tejpar S
J Clin Oncol; 2009 Oct; 27(30):5068-74. PubMed ID: 19738126
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.
Lurje G; Nagashima F; Zhang W; Yang D; Chang HM; Gordon MA; El-Khoueiry A; Husain H; Wilson PM; Ladner RD; Mauro DJ; Langer C; Rowinsky EK; Lenz HJ
Clin Cancer Res; 2008 Dec; 14(23):7884-95. PubMed ID: 19047118
[TBL] [Abstract][Full Text] [Related]
4. K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
Karapetis CS; Khambata-Ford S; Jonker DJ; O'Callaghan CJ; Tu D; Tebbutt NC; Simes RJ; Chalchal H; Shapiro JD; Robitaille S; Price TJ; Shepherd L; Au HJ; Langer C; Moore MJ; Zalcberg JR
N Engl J Med; 2008 Oct; 359(17):1757-65. PubMed ID: 18946061
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.
Pentheroudakis G; Kotoula V; De Roock W; Kouvatseas G; Papakostas P; Makatsoris T; Papamichael D; Xanthakis I; Sgouros J; Televantou D; Kafiri G; Tsamandas AC; Razis E; Galani E; Bafaloukos D; Efstratiou I; Bompolaki I; Pectasides D; Pavlidis N; Tejpar S; Fountzilas G
BMC Cancer; 2013 Feb; 13():49. PubMed ID: 23374602
[TBL] [Abstract][Full Text] [Related]
6. Correlation between gene expression of IGF-1R pathway markers and cetuximab benefit in metastatic colorectal cancer.
Huang F; Xu LA; Khambata-Ford S
Clin Cancer Res; 2012 Feb; 18(4):1156-66. PubMed ID: 22294722
[TBL] [Abstract][Full Text] [Related]
7. Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).
Cushman SM; Jiang C; Hatch AJ; Shterev I; Sibley AB; Niedzwiecki D; Venook AP; Owzar K; Hurwitz HI; Nixon AB
Clin Cancer Res; 2015 Mar; 21(5):1078-86. PubMed ID: 25520391
[TBL] [Abstract][Full Text] [Related]
8. Association between serum ligands and the skin toxicity of anti-epidermal growth factor receptor antibody in metastatic colorectal cancer.
Takahashi N; Yamada Y; Furuta K; Nagashima K; Kubo A; Sasaki Y; Shoji H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Hamaguchi T; Shimada Y
Cancer Sci; 2015 May; 106(5):604-10. PubMed ID: 25707609
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy.
Llovet P; Sastre J; Ortega JS; Bando I; Ferrer M; García-Alfonso P; Donnay O; Carrato A; Jiménez A; Aranda E; León A; Grávalos C; Cámara JC; Feliú J; Sanchíz B; Caldés T; Díaz-Rubio E
Mol Diagn Ther; 2015 Dec; 19(6):397-408. PubMed ID: 26341080
[TBL] [Abstract][Full Text] [Related]
10. EGFR fluorescence in situ hybridization pattern of chromosome 7 disomy predicts resistance to cetuximab in KRAS wild-type metastatic colorectal cancer patients.
Li YH; Wang F; Shen L; Deng YM; Shao Q; Feng F; An X; Wang FH; Wang ZQ; Xu RH; Shao JY
Clin Cancer Res; 2011 Jan; 17(2):382-90. PubMed ID: 20884623
[TBL] [Abstract][Full Text] [Related]
11. Amphiregulin and Epiregulin mRNA expression in primary colorectal cancer and corresponding liver metastases.
Kuramochi H; Nakajima G; Kaneko Y; Nakamura A; Inoue Y; Yamamoto M; Hayashi K
BMC Cancer; 2012 Mar; 12():88. PubMed ID: 22409860
[TBL] [Abstract][Full Text] [Related]
12. [Predictive factors of response to anti-EGFR treatments in colorectal cancer].
Lièvre A; Laurent-Puig P
Bull Cancer; 2008 Jan; 95(1):133-40. PubMed ID: 18230579
[TBL] [Abstract][Full Text] [Related]
13. Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial).
Stahler A; Heinemann V; Giessen-Jung C; Crispin A; Schalhorn A; Stintzing S; Fischer von Weikersthal L; Vehling-Kaiser U; Stauch M; Quietzsch D; Held S; von Einem JC; Holch J; Neumann J; Kirchner T; Jung A; Modest DP
Int J Cancer; 2016 Feb; 138(3):739-46. PubMed ID: 26284333
[TBL] [Abstract][Full Text] [Related]
14. The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab.
Strimpakos A; Pentheroudakis G; Kotoula V; De Roock W; Kouvatseas G; Papakostas P; Makatsoris T; Papamichael D; Andreadou A; Sgouros J; Zizi-Sermpetzoglou A; Kominea A; Televantou D; Razis E; Galani E; Pectasides D; Tejpar S; Syrigos K; Fountzilas G
Clin Colorectal Cancer; 2013 Dec; 12(4):267-274.e2. PubMed ID: 24050852
[TBL] [Abstract][Full Text] [Related]
15. [Correlation between the presence of Kras mutation and the presence of the proteins epiregulin and amphiregulin in colon cancer tissue].
Levi Y; Barshack I; Avivi K; Bar-ILan D; Gutman M; Aderka D; Berger R; Yacobi R
Harefuah; 2013 Jun; 152(6):326-9, 369. PubMed ID: 23885463
[TBL] [Abstract][Full Text] [Related]
16. Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells.
Oliveras-Ferraros C; Cufí S; Queralt B; Vazquez-Martin A; Martin-Castillo B; de Llorens R; Bosch-Barrera J; Brunet J; Menendez JA
Br J Cancer; 2012 Apr; 106(8):1406-14. PubMed ID: 22491422
[TBL] [Abstract][Full Text] [Related]
17. Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer.
Jonker DJ; Karapetis CS; Harbison C; O'Callaghan CJ; Tu D; Simes RJ; Malone DP; Langer C; Tebbutt N; Price TJ; Shapiro J; Siu LL; Wong RP; Bjarnason G; Moore MJ; Zalcberg JR; Khambata-Ford S
Br J Cancer; 2014 Feb; 110(3):648-55. PubMed ID: 24335920
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number.
Italiano A; Follana P; Caroli FX; Badetti JL; Benchimol D; Garnier G; Gugenheim J; Haudebourg J; Keslair F; Lesbats G; Lledo G; Roussel JF; Pedeutour F; François E
Ann Surg Oncol; 2008 Feb; 15(2):649-54. PubMed ID: 17987340
[TBL] [Abstract][Full Text] [Related]
19. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.
Ince WL; Jubb AM; Holden SN; Holmgren EB; Tobin P; Sridhar M; Hurwitz HI; Kabbinavar F; Novotny WF; Hillan KJ; Koeppen H
J Natl Cancer Inst; 2005 Jul; 97(13):981-9. PubMed ID: 15998951
[TBL] [Abstract][Full Text] [Related]
20. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.
Zhang W; Gordon M; Schultheis AM; Yang DY; Nagashima F; Azuma M; Chang HM; Borucka E; Lurje G; Sherrod AE; Iqbal S; Groshen S; Lenz HJ
J Clin Oncol; 2007 Aug; 25(24):3712-8. PubMed ID: 17704420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
